[
    [
        {
            "time": "2020-01-01",
            "original_text": "Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "quarterly deals",
                    "CFO"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Eli Lilly targets quarterly deals of $1 billion-$5 billion in 2020 - CFO",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-01-01",
            "original_text": "Eli Lilly (LLY) Gains But Lags Market: What You Should Know",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "Gains",
                    "Lags Market"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Eli Lilly (LLY) Gains But Lags Market: What You Should Know",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-01",
            "original_text": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement",
            "features": {
                "keywords": [
                    "Lilly",
                    "Financial Results",
                    "Conference Call"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly Confirms Date and Conference Call for Fourth-Quarter 2019 Financial Results Announcement",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2020-01-01",
            "original_text": "FDA Risks Sacrificing Its Standards for Speed",
            "features": {
                "keywords": [
                    "FDA",
                    "Standards",
                    "Speed"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "regulatory"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "FDA Risks Sacrificing Its Standards for Speed",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-01",
            "original_text": "J&J Seeks Label Expansion for Spravato Nasal Spray in EU",
            "features": {
                "keywords": [
                    "J&J",
                    "Spravato",
                    "Label Expansion",
                    "EU"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "J&J Seeks Label Expansion for Spravato Nasal Spray in EU",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-01",
            "original_text": "Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA",
            "features": {
                "keywords": [
                    "Bristol-Myers",
                    "Opdivo-Yervoy",
                    "sBLA",
                    "NSCLC",
                    "FDA"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]